Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015

Abstract

Prostate cancer is the most commonly diagnosed solid organ malignancy in the United States and remains the second leading cause of cancer deaths among American men. Approximately 220,000 new diagnoses of prostate cancer and over 27,000 deaths were estimated in the U.S. in 2015.¹ x 1 Siegel, R.L., Miller, K.D., and Jemal, A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5 Crossref | PubMed | Scopus (7654) | Google Scholar See all References Prostate cancer deaths are typically the result of metastatic castration-resistant prostate cancer, and historically the median survival for men with mCRPC has been less than two years. The recent availability of novel treatments for mCRPC has given a resurgence of hope for these men as studies now demonstrate improved survival with a variety of new agents. However, the unfortunate reality is that mCRPC remains an incurable disease, and it is against this backdrop that we look to the future with cautious optimism and new hope for scientific discovery.